GLPwatch

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

NCT07220759 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the effect of the medication cagrilintide on weight loss in adults who have overweight or obesity along with type 2 diabetes.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 330 people Planned (estimated).
Who can join Ages 18+ · all sexes
Timeline Started 2025-11 · est. completion 2027-06
Where 67 sites · Argentina, Canada, Croatia, Czechia, Hungary, Romania, Slovakia, South Korea, Switzerland, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT07220759 ↗

Description as written by the study sponsor.

This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.

Treatments tested

Main thing measuredRelative change in body weight
SponsorNovo Nordisk A/S
Conditions studiedOverweight, Obesity, Type 2 Diabetes
GLP-1 drugs cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07220759 ↗